These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 9677439)

  • 21. [Results of low dosage cyclic interferon-gamma therapy of metastatic renal cell carcinoma].
    Hofmockel G; Wirth MP; Heimbach D; Frohmüller HG
    Urologe A; 1993 Jul; 32(4):290-4. PubMed ID: 8372410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
    Négrier S; Perol D; Ravaud A; Bay JO; Oudard S; Chabaud S; Fargeot P; Delva R; Deplanque G; Gravis G; Escudier B;
    Clin Cancer Res; 2008 Sep; 14(18):5907-12. PubMed ID: 18794104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical efficacy and T-lymphocyte subset, serum interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), interleukin-2(IL-2) levels on treatment of chronic aplastic anemia patients by shenfu injection combined with stanozol and cyclosporin A].
    Wang SY; Wei YF; Du HL; Ren LL; Li SH
    Zhongguo Zhong Yao Za Zhi; 2005 Mar; 30(5):383-5. PubMed ID: 15806975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of TNF-alpha and retinoic acid on the proliferation of the clear cell and chromophilic types of human renal cell carcinoma in vitro.
    Gerharz CD; Ramp U; Reinecke P; Ressler U; Dienst M; Marx N; Friebe U; Engers R; Pollow K; Gabbert HE
    Anticancer Res; 1996; 16(4A):1633-41. PubMed ID: 8712681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
    Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
    Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.
    Pacheco AV; Rasila K; Lee SJ; Rabinowitz I; Elias L; Lee FC; Verschraegen CF
    Urol Oncol; 2008; 26(6):610-5. PubMed ID: 18367103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multi-cytokine therapy for advanced renal cell carcinoma: determination of the minimal effective dose.
    Hamada I; Kato M; Okada K
    Anticancer Res; 2002; 22(4):2429-36. PubMed ID: 12174939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity.
    Robak E; Sysa-Jedrzejewska A; Dziankowska B; Torzecka D; Chojnowski K; Robak T
    Arch Immunol Ther Exp (Warsz); 1998; 46(6):375-80. PubMed ID: 9883317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune reactive proteins in renal cell carcinoma patients treated by IFN alpha alone or in combination with vinblastine.
    Juranić Z; Stanojević-Bakić N; Maletić V; Borkovacki R
    Neoplasma; 1994; 41(4):229-32. PubMed ID: 7935998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
    Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
    Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Standard interleukin-2 (IL-2) and interferon-alpha immunotherapy versus an IL-2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma.
    Naglieri E; Gebbia V; Durini E; Lelli G; Abbate I; Selvaggi FP; Di Tonno P; Colucci G
    Anticancer Res; 1998; 18(3B):2021-6. PubMed ID: 9677460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-modal treatment of primarily using continuous subcutaneous interferon-alpha injection in combination with surgery and/or radiotherapy.
    Maruoka M; Fujimura M; Kawamura K; Suzuki S; Hamano M; Nishikawa Y; Nagayama T
    Int J Urol; 2005 May; 12(5):442-8. PubMed ID: 15948742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Influence of immunological parameters on the effectiveness of systemic and loco-regional immunotherapy in disseminated renal carcinoma].
    Granov AM; Molchanov OE; Karelin MI; Shkol'nik MI; Krotova OA
    Vopr Onkol; 2009; 55(5):580-5. PubMed ID: 20020653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
    Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.
    Culine S; Iborra F; Mottet N; Avancès C; de Graeve B; Volpé P; Vignoud J; Bringer JP; Marroncle M; Le Pellec L; Ayuso D; Jansen E; Faix A; Rebillard X
    Am J Clin Oncol; 2006 Apr; 29(2):148-52. PubMed ID: 16601433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha.
    Duensing S; Hadam M; Körfer A; Schomburg A; Menzel T; Grosse J; Kirchner H; Poliwoda H; Atzpodien J
    Mol Biother; 1992 Dec; 4(4):170-3. PubMed ID: 1282326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
    Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
    Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb.
    Madej A; Okopien B; Kowalski J; Zielinski M; Wysocki J; Szygula B; Kalina Z; Herman ZS
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):345-9. PubMed ID: 9660044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.